Antibodies News and Research

RSS

New high-yield method for efficient production of birch pollen allergen for Immunotherapy

Allergies can significantly affect health and quality of life. While allergen immunotherapy provides long-lasting therapeutic relief to people suffering from environmental allergies, the therapy can last several years and requires large amounts of allergen.

11 May 2020

Italy develops vaccine candidate that neutralizes SARS-CoV-2 in mice

As the world grapples with the coronavirus disease (COVID-19), scientists race to develop treatments and vaccines to combat the viral infection. Though many ongoing trials show promise in fighting the novel coronavirus, Italian researchers claim they have developed a vaccine that can neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in animal cells.

10 May 2020

Human neutralizing antibody pair blocks COVID-19-ACE2 binding

With the ongoing COVID-19 pandemic carving its deadly path across the world, and no end in sight in the immediate future, researchers are working furiously to bring out an effective therapeutic drug or vaccine that will stop the virus in its tracks.

10 May 2020

COVID-19 could accelerate activation of dormant tuberculosis (TB)

The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and well over 282,000 deaths. A new study published on the preprint server bioRxiv in May 2020 suggests that the long-term impact of the virus could include activation of dormant bacterial infections like tuberculosis (TB).

10 May 2020

Neutralizing SARS-CoV-2 via S protein

A new study published on the preprint server bioRxiv* in May 2020 reports on a method to block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by destroying its main spike protein, which is responsible for attachment to the host cell membrane.

10 May 2020

Researchers discover new type of antigen-presenting immune cell

With a discovery that could rewrite the immunology textbooks, an international group of scientists, including the teams of Bart Lambrecht, Martin Guilliams, Hamida Hammad, and Charlotte Scott (all from the VIB-UGent Center for Inflammation Research) identified a new type of antigen-presenting immune cell.

8 May 2020

More selective elimination of leukemic and hematopoietic stem cells

Acute myeloid leukemia is an aggressive cancer of the blood-forming system. It affects the hematopoietic stem cells, or blood stem cells, of various white blood cells and of the red blood cells and platelets.

8 May 2020

HMGB1 protein may play a key role in pulmonary inflammation, tissue damage in severe COVID-19 cases

In severe cases of COVID-19, a massive release of the endogenous protein HMGB1 in the lungs may contribute to pulmonary inflammation and tissue damage, according to a review article published today in the scientific journal Molecular Medicine.

8 May 2020

Looking for a path to reopen, employers weigh COVID testing of workers

Just a few miles from Disney World, Harris Rosen's hotel empire is mostly closed because of the COVID pandemic.

8 May 2020

Researchers develop vaccine for virus associated with type 1 diabetes

According to many observations, certain virus infections may play a part in the autoimmune attack that leads to type 1 diabetes. Researchers at Karolinska Institutet and at the universities of Jyväskylä and Tampere have now produced a vaccine for these viruses in the hope that it could provide protection against the disease. The study is published 6 May 2020 in the scientific journal Science Advances.

8 May 2020

Intervention strategy based on shield immunity could reduce risk of expanding economic activity

While attention remains focused on the number of COVID-19 deaths and new cases, a separate statistic - the number of recovered patients - may be equally important to the goal of minimizing the pandemic's infection rate as shelter-in-place orders are lifted.

8 May 2020

Repurposing existing drugs is a more rapid alternative than developing COVID-19 vaccine

Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.

8 May 2020

Children are immune prepared for SARS-CoV-2

At least 30 new diseases have emerged in the last 20 years and now together threaten the health of hundreds of millions of people. For many of these diseases, there is no treatment, cure, or vaccine. While most of these diseases are dangerous to children, especially those younger than five years old, the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), seems to spare most of them.

8 May 2020

Antibodies from llamas may hold cure for novel coronavirus SARS-CoV-2

As scientists across the globe race to find an effective treatment for the novel coronavirus, a team of scientists believe that a four-year-old llama named Winter may hold the key to fight the coronavirus disease (COVID-19).

7 May 2020

IONTAS announces a new collaboration to identify novel immunotherapy targets

Antibody discovery agreement will support the development of new therapeutics for acute and chronic inflammatory syndromes.

From FairJourney Biologics 7 May 2020

Twist Bioscience Identifies Competitive Antibodies for SARS-CoV-2

Twist Bioscience Corporation has identified competitive antibodies to SARS-CoV-2, which could potentially be used for diagnostic tests and treatments.

7 May 2020

Harmful effects of BPA can be reversed by administering coenzyme Q10

Exposure to bisphenol A (BPA), an industrial chemical used to make certain plastics and resins, inner coatings for food cans and bottle tops, thermal paper used in store receipts, dental sealants and so on, is a concern because of possible adverse health effects, including a reduction in fertility.

7 May 2020

Low CD8 and NK cell counts in the lung linked to high SARS-CoV-2 ACE2 receptor levels

A new study published on the preprint server bioRxiv in April 2020 reports that low levels of specific immune cells, namely, CD8 T cells and NK cells, are linked to higher expression of the ACE2 molecule, which acts as a receptor for the CoV.

6 May 2020

GeoVax and Sino Biological establish exclusive supply agreement for research grade bioreagents related to SARS-CoV-2 (COVID-19) vaccine development

GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that Beijing- and Philadelphia-based Sino Biological, Inc. will be its exclusive supplier of SARS-CoV-2 (COVID-19) bioreagent research products.

From Sino Biological Inc. 6 May 2020

OXGENE™ reports third consecutive year of 100% year on year revenue growth

OXGENE™ has more than doubled its annual revenue in the financial year just closed, in the third consecutive year of 100% year on year revenue growth.

From OXGENE 6 May 2020